Orforglipron is now approved and on the market under the brand name Foundayo. The FDA approved it on April 1, 2026, for adults with obesity, or overweight with weight-related medical problems, making it the first GLP-1 pill that can be taken any time of day with no food or water restrictions. It’s a once-daily tablet that produced about 12.4% average weight loss at the highest dose in trials. Pricing starts at about $25 per month with commercial insurance and $149 per month for self-pay. Here’s what it is, how well it works, and how it stacks up against other options.<\/p>\n
Foundayo (orforglipron) is a once-daily oral GLP-1 receptor agonist from Eli Lilly. Unlike semaglutide, which is a peptide that has to be injected or taken under strict fasting conditions, orforglipron is a small molecule that absorbs well by mouth. That’s its headline advantage: you can take it any time of day, with or without food, and no water restrictions. It became available through LillyDirect in early April 2026, with broader pharmacy and telehealth availability following.<\/p>\n
It’s worth being clear about the difference between Foundayo and oral Wegovy. Both are weight loss pills, but oral Wegovy is semaglutide (a peptide that needs a fasting window), while Foundayo is a non-peptide molecule with no timing restrictions. They’re different drugs that happen to share a delivery format.<\/p>\n
In its Phase 3 obesity program, orforglipron produced about 12.4% average weight loss at the highest dose. That puts it roughly in line with injectable semaglutide on the lower end, and below the most effective injectable, tirzepatide, which reaches about 21% to 22.5%. In general, the oral pills in this category deliver somewhat less weight loss than the top weekly injections, but they trade some efficacy for the convenience of a daily pill with no special routine.<\/p>\n
For context, an earlier orforglipron study in adults with obesity showed about 14.7% weight loss at 36 weeks on the highest dose tested, similar to semaglutide’s roughly 15% in its main trial.<\/p>\n
| Feature<\/th>\n | Foundayo (orforglipron)<\/th>\n<\/tr>\n<\/thead>\n |
|---|---|
| Type<\/td>\n | Non-peptide oral GLP-1 pill<\/td>\n<\/tr>\n |
| Status<\/td>\n | FDA approved (April 2026)<\/td>\n<\/tr>\n |
| Dosing<\/td>\n | Once daily, any time, no food\/water rules<\/td>\n<\/tr>\n |
| Average weight loss<\/td>\n | ~12.4% (highest dose)<\/td>\n<\/tr>\n |
| Cost<\/td>\n | ~$25\/month (commercial insurance), ~$149\/month (self-pay)<\/td>\n<\/tr>\n |
| Maker<\/td>\n | Eli Lilly<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\nWhat It Costs<\/h3>\nThis is where Foundayo stands out. Eligible people with commercial insurance may pay as little as about $25 per month using the manufacturer savings card, and self-pay pricing starts around $149 per month for the lowest dose. That’s well below the cash list price of injectable GLP-1 medications, which run roughly $1,000 to $1,350 per month before any discounts. Part of the reason is that oral tablets are cheaper to manufacture than sterile injectables. Actual out-of-pocket cost still depends on your insurance, plan, and dose.<\/p>\n Side Effects<\/h3>\nFoundayo’s side effects are the typical GLP-1 ones: nausea, constipation, diarrhea, vomiting, and indigestion, usually worst during the first weeks and after dose increases, then easing as your body adjusts. It carries a boxed warning about a potential risk of thyroid C-cell tumors based on animal studies, and shouldn’t be used by people with a personal or family history of medullary thyroid carcinoma or MEN 2. One reassuring note from its trials: despite being a small molecule (a class where liver effects are always a concern), orforglipron did not show liver safety problems in its studies.<\/p>\n How Foundayo Compares to Your Options<\/h3>\nIf you want a pill and flexibility matters most, Foundayo’s no-restriction dosing is its biggest selling point over both oral Wegovy (which requires fasting) and the weekly injections (which require a shot). If maximum weight loss is the priority, the injectables, especially tirzepatide, still lead. For many people, the deciding factors are convenience, cost, and tolerability rather than a few percentage points of weight loss. Our semaglutide vs orforglipron comparison<\/a> and the full orforglipron side effect profile<\/a> go deeper, and you can see what an effective injectable can do<\/a> for comparison.<\/p>\n |